OXiGENE to Collaborate With NCI/CTEP, GOG on Phase 2 Study of ZYBRESTAT in Patients With Relapsed Ovarian Cancer (Nasdaq:OXGND)
Links shared publicly online about this topic.
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer. Under the terms of the agreement, OXiGENE View full resource at globenewswire.com
Tags: Cancer, Ovarian Cancer, Eye, Disease and Condition, Phase 2 Clinical Trial, Women's Health, disease
Most Recently Shared on February 15, 2011 at 4:58 pm By: